bluebird bio (BLUE) Earning Somewhat Favorable Press Coverage, Report Finds
News headlines about bluebird bio (NASDAQ:BLUE) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. bluebird bio earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.7802849130191 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Several research analysts have commented on the stock. SunTrust Banks, Inc. lifted their price objective on shares of bluebird bio from $108.00 to $163.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Jefferies Group LLC reaffirmed a “hold” rating and set a $130.00 price objective on shares of bluebird bio in a research note on Friday, November 3rd. Morgan Stanley raised shares of bluebird bio from an “underweight” rating to an “equal weight” rating in a research note on Friday, November 3rd. Barclays PLC lifted their price objective on shares of bluebird bio from $151.00 to $162.00 and gave the stock an “overweight” rating in a research note on Thursday, November 2nd. Finally, Maxim Group reaffirmed a “buy” rating and set a $170.00 price objective on shares of bluebird bio in a research note on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $131.05.
Shares of bluebird bio (NASDAQ BLUE) traded down $1.50 on Tuesday, hitting $153.05. The stock had a trading volume of 255,005 shares, compared to its average volume of 843,318. bluebird bio has a fifty-two week low of $55.65 and a fifty-two week high of $164.80.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The company had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business’s quarterly revenue was up 397.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($2.07) EPS. sell-side analysts expect that bluebird bio will post -6.68 earnings per share for the current fiscal year.
In other bluebird bio news, insider Jeffrey T. Walsh sold 1,250 shares of bluebird bio stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $107.06, for a total transaction of $133,825.00. Following the transaction, the insider now owns 28,555 shares of the company’s stock, valued at $3,057,098.30. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Daniel Lynch sold 500 shares of bluebird bio stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $120.00, for a total value of $60,000.00. Following the transaction, the director now directly owns 3,300 shares in the company, valued at approximately $396,000. The disclosure for this sale can be found here. Insiders have sold a total of 183,268 shares of company stock worth $24,077,161 in the last three months. Corporate insiders own 3.90% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “bluebird bio (BLUE) Earning Somewhat Favorable Press Coverage, Report Finds” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/14/bluebird-bio-blue-earning-somewhat-favorable-press-coverage-report-finds.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.